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ABSTRACT 
Cariprazine is a dopamine D3-preferring 
D3/D2 receptor partial agonist in late-stage clinical 
development for the treatment of bipolar disorder 
(manic/mixed and depressive episodes), as well as 
for schizophrenia, and as an adjunctive agent for 
the treatment of major depressive disorder. Three 
phase 2 or 3, 3-week, randomized controlled trials 
in bipolar mania or mixed episodes have been 
completed and reported as poster presentations or 
in press releases by the manufacturer. Superiority 
over placebo on the Young Mania Rating Scale 
total score was evidenced for daily doses 
of cariprazine 3–12 mg/day. In short-term 
randomized controlled trials, cariprazine does not 
appear to adversely impact metabolic variables, 
prolactin, or the electrocardiogram (ECG) QT 
interval. The most commonly encountered 
adverse events in the mania trials were 
extrapyramidal disorder, akathisia, insomnia, 
vomiting, restlessness, sedation, vision blurred, 
and pain in extremity in the phase 2 trial where 
this was presented in a poster, and akathisia, 
extrapyramidal disorder, tremor, dyspepsia, 
vomiting, dizziness, diarrhea, somnolence, 
restlessness, and pyrexia for the phase 3 trial 
where this was presented in a poster. With the 
exception of akathisia and extrapyramidal 
disorder, the differences in incidence versus 
placebo for these events were generally small. If 
approved by regulatory authorities, cariprazine 
would join aripiprazole as the second dopamine 
receptor partial agonist antipsychotic available 
for clinical use in persons with bipolar mania 
or mixed episodes. Cariprazine differs from 
aripiprazole in terms of dopamine D3 receptor 
selectivity. Further studies would be helpful to 
discern the distinguishing features of cariprazine 
from other antimanic agents. 
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INTRODUCTION
Although there are several agents that have received 
regulatory approval for the treatment of bipolar 
disorder, it is often difficult to select the treatment(s) 
that will result in sufficient reduction in symptoms 
together with reasonable tolerability and safety. 
Moreover, although most available treatments are 
approved for the treatment of acute mania, fewer 
are approved for both manic and mixed episodes, 
fewer still for maintenance treatment, and only two 
for the treatment of acute bipolar depression [1, 2]. 
The agents themselves vary greatly in terms of ease 
of use and tolerability [1, 2]. 
Cariprazine is a new second-generation 
antipsychotic, in the late-stage of clinical 
development for the treatment of bipolar disorder 
(manic/mixed and depressive episodes), as well as 
for schizophrenia and as an adjunctive agent for 
the treatment of major depressive disorder. The 
intent of this review is to describe the efficacy, 
tolerability, and potential place in therapy of 
cariprazine for the treatment of bipolar disorder. A 
PubMed search was conducted on October 31 2012 
using the search terms “cariprazine,” “RGH-188,” 
and “RGH 188” without any date or language 
restrictions. The resulting 15 publications and their 
reference lists were then specifically examined for 
primary sources of information with emphasis 
on the use of cariprazine in persons with bipolar 
disorder. A query of the ClinicalTrials.gov website 
on October 31 2012 yielded 18 separate records 
and provided additional information regarding 
registered trials of cariprazine. The abstract books 
for the annual scientific meetings of the American 
Psychiatric Association (2008–2012) [3–7], Institute 
on Psychiatric Services of the American Psychiatric 
Association (2008–2012) [8–12], New Clinical 
Drug Evaluation Unit (2008–2012) [13–17], and 
American College of Neuropsychopharmacology 
(2008–2011) [18–21], were also examined and 
yielded additional relevant data that have not 
yet been published as full reports in peer-refereed 
journals. Whenever possible, reproductions of the 
poster presentations were obtained in digital PDF 
format from the authors. Press releases from the 
manufacturer were also reviewed for preliminary 
clinical trial results that have not yet been 
presented at scientific meetings. A similar search 
strategy has been used by the author in other 
reviews of cariprazine, including a companion 
review regarding cariprazine for the treatment of 
schizophrenia [22], and a systematic review with 
emphasis on the chemistry, pharmacodynamics, 
and pharmacokinetics of cariprazine [23].
PHARMACODYNAMICS AND 
PHARMACOKINETICS
The pharmacodynamics and pharmacokinetics 
of cariprazine are reviewed in more detail 
elsewhere [22, 23]. Cariprazine is a dopamine 
D3-preferring D3/D2 receptor partial agonist [24]. 
The in vitro binding profile of cariprazine is 
summarized in Table 1. 
Table 1  In vitro binding anities for cariprazine in human 
receptors [24]
Receptor Ki (nM) Comments
Dopamine D3 0.085 Partial agonist
Dopamine D2L 0.49 Partial agonist
Dopamine D2S 0.69 Partial agonist
Serotonin 5-HT2B 0.58 Antagonist
Serotonin 5-HT1A 3 Partial agonist
Serotonin 5-HT2A 19 Antagonist
Histamine H1 23 Antagonist
Serotonin 5-HT7 111 Antagonist
Serotonin 5-HT2C 134 Antagonist
Ki binding anity
Lower values denotes higher anity
Low anity was observed for all tested adrenergic 
receptors
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Although the pharmacokinetics of cariprazine 
in subjects with bipolar disorder is not 
known, the pharmacokinetics of cariprazine 
was tested in small short-term studies in 
both healthy volunteers and in subjects 
with schizophrenia, with similar results [25]. 
Maximum concentration was observed in 3−4 h 
under fasting conditions, with food causing 
a slight delay but no significant effect on the 
extent of absorption. The mean half-life for 
cariprazine was 2–5 days over a dose range of 
1.5–12.5 mg in the subjects with schizophrenia. 
Cariprazine is metabolized by cytochrome 
P450 3A4 (CYP3A4) and, to a lesser extent, 
by cytochrome P450 2D6 (CYP2D6) [26]. 
There are two active metabolites of note, 
desmethyl-cariprazine and didesmethyl-
cariprazine. Didesmethyl-cariprazine’s half-life is 
substantially longer than that for cariprazine and 
systemic exposure to didesmethyl-cariprazine can 
be several times higher than that for cariprazine.
SHORT-TERM CLINICAL TRIALS
Overview 
Table 2 [27–31] provides an overview of the 
double-blind randomized efficacy trials of 
cariprazine for bipolar disorder in adults, as 
conducted by the manufacturer. Results from 
one phase 2 (RGH-MD-31 [27]) and two phase 3 
(RGH-MD-32 [28] and RGH-MD-33 [29]) short-
term, randomized controlled trials of cariprazine 
in subjects with bipolar mania/mixed episodes 
have been reported in posters at scientific 
meetings [27, 28] and in a press release from 
the manufacturer [29]. Results from a study 
in bipolar depression have been reported in a 
press release [30], and another study in bipolar 
depression is in progress [31]. 
In the studies for bipolar mania/mixed 
episodes, subjects could receive up to 3 weeks 
of randomized treatment. The primary efficacy 
Table 2  Summary of double-blind randomized ecacy trials of cariprazine for bipolar disorder in adults, as conducted by 
the manufacturer
Study Phase Length 
(weeks)







RGH-MD-31 [27] 2 3 238 3.0–12.0 mg (118) None 120 Acute mania. Unpublished. 
Presented as a poster. 
RGH-MD-32 [28] 3 3 312 3.0–12.0 mg (158) None 154 Acute mania. Unpublished. 
Presented as a poster.
RGH-MD-33 [29] 3 3 497 3.0–6.0 mg (167),  
6.0–12.0 mg (169)
None 161 Acute mania. Unpublished. 
Limited information is 
available in a press release.
RGH-MD-52 [30] 2 8 233 0.25–0.75 mg (ND),  
1.5–3.0 mg (ND)
None ND Bipolar depression. 
Unpublished. Limited 
information is available in a 
press release.
RGH-MD-56 [31] 2 8 600 0.75 mg (NA),  
1.5 mg (NA),  
3.0 mg (NA)
None NA Ongoing study in bipolar 
depression. 
NA not applicable, ND not disclosed
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measure was the Young Mania Rating Scale 
(YMRS) total score; the primary outcome was 
change from baseline on the YMRS total score at 
the 3-week endpoint. Figure 1 [27–29] provides 
an overview of the YMRS total score difference 
from placebo at endpoint for the three studies. 
Table 3 [27, 28] provides an overview of the 
outcomes of response and remission for the two 
studies where this was reported. All cariprazine 
treatment arms were statistically superior to 
placebo on the primary outcome. There were no 
active controls. 
RGH-MD-31 
This flexible-dose study was conducted 
internationally, with approximately 60% of 
the subjects enrolled at US sites [27]. Inclusion 
criteria included a diagnosis of bipolar I disorder, 
manic or mixed type, with or without psychotic 
features, YMRS score of at least 20, with a score 
of ≥4 on at least two of four of the following 
YMRS items: irritability, speech, content, 
disruptive/aggressive behavior. Subjects were 
18–65 years of age. Excluded were persons with 
rapid cycling, those in their first manic episode, 
subjects considered a suicide risk, and subjects 
with a Montgomery-Asberg Depression Rating 
Scale (MADRS) score of ≥18. After up to 4 days of 
Fig. 1  Cariprazine ecacy outcomes: Young Mania Rating 
Scale (YMRS) total score dierence from placebo, by study 
and daily dose, for three 3-week randomized controlled 
trials. All cariprazine arms were statistically signicantly 
superior to placebo. In RGH-MD-31 [27], baseline YMRS 
total score was 30.2 for placebo and 30.6 for cariprazine; 
last observation carried forward (LOCF) change was –7.2 
for placebo and –13.3 for cariprazine. In RGH-MD-32 
[28], baseline YMRS total score was 32.1 for placebo 
and 32.3 for cariprazine; mixed-eects model of repeated 
measures (MMRM) change was displayed graphically 
in the poster and was approximately –15 for placebo 
and approximately –19 for cariprazine at day 21, and 
the reported least squares mean dierence (LSMD) was 
reported as –4.3. Limited information has been reported 
regarding RGH-MD-33 [29]; the press release reports that 
the LSMD obtained by MMRM at day 21 was –6.1 for 
cariprazine 3–6 mg/day and –5.9 points for cariprazine 























3.0–12.0 mg 3.0–6.0 mg
RGH-MD-31 [27] RGH-MD-32 [28] RGH-MD-33 [29]
6.0–12.0 mg
Table 3  Responder and remission rates and number needed to treat (NNT) versus placebo as reported from short-term, 
randomized controlled trials of cariprazine for manic/mixed episodes of bipolar disorder
RGH-MD-31 [27] RGH-MD-32 [28]
Cariprazine 










Responders 48% 25% 5 59% 44% 7
Remitters 42% 23% 6 52% 35% 6
Response is dened as a decrease in the Young Mania Rating Scale of at least 50% from baseline, last observation carried 
forward (LOCF)
Remission is dened as a Young Mania Rating Scale total score no greater than 12 at LOCF endpoint
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washout off medications in an inpatient setting, 
238 subjects were randomized (safety population 
included 236 subjects) to cariprazine or placebo. 
Subjects randomized to cariprazine received 
1.5 mg/day on day 1, and then titrated within 
the range of 3–12 mg/day based on response 
and tolerability as judged by the investigator. 
Hospitalization was mandatory during screening 
and the first 2 weeks of double-blind treatment. 
Discharge was possible on day 14 or after if the 
Clinical Global Impressions Severity (CGI-S) 
score was no greater than 3, the subject was 
otherwise not at significant risk for suicide or 
violent behavior, and was ready for discharge 
in the opinion of the investigator. Mean age of 
subjects ranged from 38 to 39 years across the two 
treatment arms; male gender ranged from 65% 
to 68%; white race ranged from 40% to 47%; and 
baseline YMRS total score ranged from 30 to 31. 
In total, 36–38% of patients discontinued the 
trial prematurely. Mean duration of treatment 
was 17 days and the overall mean daily dose 
was 8.8 mg/day. Cariprazine was statistically 
significantly superior to placebo on the primary 
efficacy parameter and on the CGI-S, Clinical 
Global Impressions-Improvement (CGI-I), and 
Positive and Negative Syndrome Scale (PANSS), 
but not on the MADRS. Compared with placebo, 
cariprazine-treated subjects had significantly 
greater rates of YMRS response (at least 50% 
reduction from baseline) and remission (total 
score no greater than 12). 
In an analysis of single items from the YMRS, 
for each YMRS item cariprazine was statistically 
significantly superior to placebo. Mean changes in 
clinical laboratory values were small and similar 
between the groups except for slightly higher 
levels in liver enzymes for the cariprazine group. 
Mean changes in blood pressure and pulse were 
higher in the cariprazine group relative to placebo. 
The incidence of orthostatic hypotension or ECG 
changes was similar between cariprazine- and 
placebo-treated subjects. There was a higher 
incidence of extrapyramidal-related symptoms 
in the cariprazine group relative to placebo. 
Treatment emergent adverse events with an 
incidence at least 5% for any of the cariprazine 
treatment arms and at least twice that for placebo 
were extrapyramidal disorder, akathisia, insomnia, 
vomiting, restlessness, sedation, vision blurred, 
and pain in extremity. Differences from placebo 
were generally small except for extrapyramidal 
disorder and akathisia where the numbers needed 
to harm (NNH) versus placebo were 7 and 8, 
respectively (see Table 4a [27]).
RGH-MD-32 
This flexible-dose study was conducted 
internationally [28]. Inclusion criteria included 
a diagnosis of bipolar I disorder, manic or mixed 
type, with or without psychotic features, YMRS 
score of ≥20, with a score of ≥4 on at least two 
of four of the following YMRS items: irritability, 
speech, content, disruptive/aggressive behavior. 
Subjects were 18–65 years of age. Excluded were 
persons with rapid cycling, those in their first 
manic episode, subjects considered a suicide 
risk, and subjects with a MADRS score of ≥18. 
After up to 4–7 days of washout off medications 
in an inpatient setting, 312 subjects were 
randomized to cariprazine or placebo. Subjects 
randomized to cariprazine received 1.5 mg/day 
on day 1. Starting on day 2, the dose could be 
increased in increments of 3 mg to a maximum 
of 12 mg/day by day 7, based on patient 
response and tolerability. Hospitalization was 
mandatory during screening and the first 
2 weeks of double-blind treatment. Discharge 
was possible on day 14 or after if the CGI-S 
score was no greater than 3, the subject was 
otherwise not at significant risk for suicide or 
violent behavior, and was ready for discharge 
in the opinion of the investigator. Mean age of 
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subjects ranged from 36 to 37 years across the 
two treatment arms; male gender ranged from 
62% to 66%; white race 21%; mean body mass 
index ranged from 25 to 26 kg/m2; and baseline 
YMRS total scores were approximately 32. In 
total, 31–32% of patients discontinued the trial 
prematurely. Mean duration of treatment was 
17–18 days and the overall mean daily dose 
was 7.5 mg/day. Cariprazine was statistically 
significantly superior to placebo on the 
primary efficacy parameter and on the CGI-S, 
CGI-I, and PANSS, but not on the MADRS. 
Table 4  (a) Treatment emergent adverse events with an incidence ≥5% for cariprazine and at least twice that for placebo 
from RGH-MD-31 [27] – incidence (%) and number needed to harm (NNH) versus placebo; (b) treatment emergent 
adverse events with an incidence ≥5% for cariprazine and at least twice that for placebo from RGH-MD-32 [28] –  
incidence (%) and number needed to harm (NNH) versus placebo
(a)
Adverse event Placebo (n = 118) Cariprazine 3–12 mg/day (n = 118)
% % NNH
Extrapyramidal disorder 9.3 24.6 7
Akathisia 5.9 18.6 8
Insomnia 2.5 8.5 17
Vomiting 3.4 8.5 20
Restlessness 0.8 5.9 20
Sedation 0.8 5.9 20
Vision blurred 0.8 5.9 20
Pain in extremity 2.5 5.1 39
(b)
Adverse event Placebo (n = 154) Cariprazine 3–12 mg/day (n = 158)
% % NNH
Akathisia 4.5 22.8 6
Extrapyramidal disorder 1.9 15.2 8
Tremor 3.9 11.4 14
Dyspepsia 3.2 10.8 14
Vomiting 3.9 10.1 17
Dizziness 3.9 8.2 24
Diarrhea 1.3 7.0 18
Somnolence 1.3 5.7 23
Restlessness 0.6 5.7 20
Pyrexia 1.9 5.1 32
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Compared with placebo, cariprazine-treated 
subjects had significantly greater rates of YMRS 
response and remission. Mean changes in 
clinical laboratory values were generally small 
and similar between the two groups. Similar 
mean decreases in prolactin levels were observed 
with placebo and cariprazine treatment. Mean 
changes in vital signs were small and similar 
between treatment groups with the incidence of 
orthostatic hypotension being similar for placebo 
and cariprazine. Mean changes from baseline 
to end of treatment in body weight were small 
and similar between treatment groups (placebo, 
0.30 kg; cariprazine, 0.43 kg). There were no 
subjects receiving cariprazine who experienced 
an electrocardiogram (ECG) QT interval in 
excess of 500 msec. Treatment emergent adverse 
events with an incidence at least 5% for any of 
the cariprazine treatment arms and at least twice 
that for placebo were akathisia, extrapyramidal 
disorder, tremor, dyspepsia, vomiting, dizziness, 
diarrhea, somnolence, restless, and pyrexia. 
Differences from placebo were generally small 
except for akathisia and extrapyramidal disorder 
where the NNH versus placebo were 6 and 8, 
respectively (see Table 4b [28]). A total of 
15 subjects receiving cariprazine discontinued 
because of an adverse event, with five because 
of akathisia.
RGH-MD-33 
This study was conducted internationally [29]. 
Inclusion criteria included a diagnosis of bipolar 
I disorder, manic or mixed type, with or without 
psychotic features. Subjects were 18–65 years 
of age. After up to 4–7 days of washout 
off medications in an inpatient setting, 
497 subjects were randomized to cariprazine 
3–6 mg/day, cariprazine 6–12 mg/day, or placebo. 
Hospitalization was mandatory during screening 
and the first 2 weeks of double-blind treatment. 
In total, 23–30% of patients discontinued 
the trial prematurely. Statistically significant 
improvement was observed in both cariprazine 
dose groups versus placebo on the primary 
efficacy parameter. The most common adverse 
events (≥10% and twice the rate of placebo) 
observed in the study were akathisia (both 
cariprazine groups) and constipation (cariprazine 
6–12 mg/day). Discontinuations due to adverse 
events occurred in 9%, 15%, and 5% of subjects 
in the cariprazine 3–6 mg/day, 6–12 mg/day, and 
placebo groups, respectively. 
RGH-MD-52 
This exploratory study was conducted in the 
US [30]. According to additional information 
contained in the study registration on the 
ClinicalTrials.gov website [32], inclusion criteria 
included persons 18–65 years of age, diagnosis 
of bipolar I or II disorder without psychotic 
features, with a current depressive episode, 
a verified previous manic, hypomanic, or 
mixed episode, score of ≥20 on the Hamilton 
Depression Rating Scale-17 (HAMD), and score 
of ≥2 on Item 1 of the HAMD. Excluded were 
persons with a score >12 on the YMRS, or 
≥8 episodes of a mood disturbance (depression, 
mania, hypomania, or mixed state) within the 
12 months prior to visit 1. Following a washout 
period of no antipsychotic therapy for at least 
1 week, a total of 233 patients were randomized 
to cariprazine 0.25–0.75 mg/day, cariprazine 
1.5–3.0 mg/day, or placebo. The primary 
endpoint was change from baseline to week 8 
in the MADRS total score compared to placebo 
treatment. The overall difference observed 
between cariprazine and placebo-treated subjects 
was not statistically significant. Approximately 
9% of patients discontinued the study early due 
to adverse events in the high-dose study arm 
compared to 3% in the placebo arm [30]. 
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LONG-TERM CLINICAL TRIALS
Long-term data for cariprazine in bipolar disorder 
has not been publically presented. Registered on 
the ClinicalTrials.gov website is study RGH-MD-36 
[33], a 16-week, open-label, flexible-dose study of 
the safety and tolerability of cariprazine in patients 
with bipolar I disorder. Conducted internationally, 
it was completed in March 2012. 
RANDOMIZED CONTROLLED 
TRIALS IN PROGRESS
Table 2 notes an ongoing trial, RGH-MD-56, 
an 8-week study of cariprazine versus placebo 
in bipolar depression [31]. As per the study 
registration on the ClinicalTrials.gov website 
subjects with bipolar I depression without 
psychotic features, 18–65 years of age, and with 
a verified previous manic or mixed episode, 
a total HAMD score of ≥20, a HAMD Item 1 
score of ≥2, and a CGI-S of ≥4 would be eligible 
for randomization to cariprazine 0.75, 1.5, 
or 3.0 mg/day, or placebo. The study is being 
conducted internationally.
OVERALL PLACE OF CARIPRAZINE 
IN THERAPY
Cariprazine represents a new treatment option 
for bipolar disorder and appears ready for 
commercialization for the indication of bipolar 
manic/mixed episodes. Efficacy and tolerability 
for this indication was established in the dose 
range of 3–12 mg/day. As observed in the short-
term clinical trials, there do not appear to be 
clinically relevant adverse effects of cariprazine 
on metabolic variables, prolactin, or the ECG 
QT interval. Additional long-term data is 
desirable to further characterize any longer-
term treatment-related changes in body weight, 
metabolic variables, and movement disorders.
A recommendation in product labeling for 
dose titration will likely mirror that used in the 
clinical trials, otherwise dosing is once daily 
without regard to meals. When comparing 
cariprazine with the commercially available 
“metabolically-friendly” second-generation 
antipsychotics that have received regulatory 
approval for the indication of manic/mixed 
episodes of bipolar disorder, cariprazine most 
resembles aripiprazole (see Table 5 [28, 34–36]). 
Number need to treat (NNT) values versus 
placebo for response and remission are available 
for two of the mania trials [27, 28] and can be 
found in Table 3. The NNT for response of 5 or 7 
is similar to that observed with data for lithium 
(NNT 4), divalproex ER (NNT 7), carbamazepine 
ER (NNT 4), olanzapine (NNT 5), risperidone 
(NNT 4), quetiapine XR (NNT 6), ziprasidone 
(NNT 7), aripiprazole (NNT 5), and asenapine 
(NNT 8) [1]. NNH values regarding akathisia for 
cariprazine versus placebo are approximately 
the same as the NNT for response, meaning 
that it may be equally likely to encounter 
one additional responder as it would be to 
encounter one additional patient experiencing 
a spontaneously reported adverse event of 
akathisia with cariprazine versus placebo. 
Provided that the akathisia is mild and time-
limited this may not be a substantial obstacle 
for using cariprazine but in persons sensitive to 
akathisia this could be problematic. NNH values 
regarding somnolence for cariprazine versus 
placebo are similar to that for aripiprazole and 
appear more favorable than that observed for 
ziprasidone or asenapine (Table 5) [28, 34–36].
Cariprazine is a potential alternative to 
aripiprazole [35, 37]. Although both cariprazine 
and aripiprazole are dopamine receptor partial 
agonists, cariprazine has a different receptor 
binding profile, with greater affinity for the 
dopamine D3 receptor as the main distinguishing 
feature. Whether this would be clinically relevant 
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requires additional randomized controlled trials 
that are specifically designed and powered to 
contrast cariprazine with aripiprazole at optimal 
doses. Regarding the latter, it is unclear which 
doses of cariprazine would offer the best balance 
in terms of efficacy and tolerability. In terms of 
drug-induced extrapyramidal adverse events 
and akathisia it will be important to further 
characterize possible dose response and the 
time course that these effects follow. This may 
be a complex undertaking, given the long half-
life of didesmethyl-cariprazine, one of the two 
important active metabolites of cariprazine. 
Cost will likely be a consideration given 
the availability of generic second-generation 
antipsychotics, including the future emergence 
of generic formulations of aripiprazole. 
However, should cariprazine receive regulatory 
approval for the treatment of bipolar depression, 
the scarcity of available alternatives for this 
indication bodes well for the commercial success 
of cariprazine. 
At present, available data are limited to short-
term trials with constrained inclusion/exclusion 
criteria that can limit their generalizability. Longer-
term trials will be necessary to further characterize 
cariprazine’s efficacy, tolerability, and safety 
profile, including effects on metabolic variables. 
Relapse prevention studies would also potentially 
inform clinicians about cariprazine’s potential for 
the prevention of manic or depressive episodes 
associated with bipolar disorder. The inclusion of 
active comparators in studies will further clarify 
cariprazine’s place in therapy. 
An important caveat is that none of the 
efficacy studies discussed have been published 
in peer-reviewed journals, and so the data 
presented must be considered preliminary and 
subject to revision. 
Logical candidates for cariprazine treatment 
would be adults with bipolar manic/mixed 
episodes for whom sedation, metabolic, or 
cardiovascular risk is a concern, and for whom 
weight gain is to be minimized or avoided. 
Table 5  Highlights of dierences and similarities among cariprazine, ziprasidone, aripiprazole, and asenapine regarding 
their adverse event proles in bipolar mania/mixed episodes in adults as reported in product labeling [34–36] and available 
information for cariprazine (taken from RGH-MD-32 [28])
Cariprazine [28] Ziprasidone [34] Aripiprazole [35] Asenapine [36]
Spontaneously reported 





















symptoms other than 
akathisia, and weight 
gain
AE – somnolence, NNH 23 6 20 (sedation) 6
AE – akathisia, NNH 6 20 12 50
Prolactin warning? No Yes No Yes
QT warning? No Yes No Yes
AE adverse event, NNH number needed to harm (calculated as the reciprocal of the incidence of the AE on the drug 
of interest minus the incidence of the AE for placebo, and then rounded to the next highest whole number) from data 
contained in product labeling (prescribing information) available from the manufacturers [34–36]
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Patients who are sensitive to akathisia and 
extrapyramidal effects will need to be monitored 
for these adverse drug reactions. 
CONCLUSIONS
If commercialized, cariprazine will be a new 
treatment option for bipolar disorder. Based 
on the short-term studies conducted by the 
manufacturer, efficacy and tolerability for 
manic/mixed episodes was established in the 
dose range of 3–12 mg/day. There doesn’t 
appear to be clinically relevant adverse effects 
of cariprazine on metabolic variables, prolactin, 
or the ECG QT interval. The incidence of 
extrapyramidal side effects and akathisia appear 
higher for cariprazine-treated subjects with 
bipolar disorder than those with schizophrenia. 
Longer-term tolerability information in subjects 
with bipolar disorder is not yet available. 
Additional clinical trials are underway for the 
use of cariprazine in bipolar depression and 
major depressive disorder. 
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